Key insights
- Abbott Laboratories hit a 52-week low amid mixed Q1 results and lowered analyst price targets. Revenue missed expectations, particularly in diabetes and respiratory segments, leading to reduced organic growth guidance. Despite this, the stock's RSI indicates it's oversold, and InvestingPro suggests it's undervalued. The company maintains a solid dividend yield and financial health, but overall, the news exerts slight bearish pressure on the broader healthcare sector.
Abbott Laboratories stock reached a 52-week low, closing at $86.15, marking a significant downturn for the company. According to InvestingPro data, the stock’s RSI suggests it has entered oversold territory, potentially signaling a buying opportunity for value investors. Over the past year, Abbott Laboratories has experienced a notable decline, with its stock price falling by 34.85%. This drop comes amid broader market challenges and specific pressures within the healthcare sector, which have impacted investor sentiment and the company’s stock performance. Despite the downturn, InvestingPro analysis indicates the stock is undervalued, appearing on the platform’s Most Undervalued list. The company maintains a "GOOD" financial health score and a dividend yield of 2.9%, with 56 consecutive years of dividend payments. InvestingPro offers 10 additional exclusive tips for ABT investors seeking deeper insights.
In other recent news, Abbott Laboratories received U.S. Food and Drug Administration clearance and CE Mark for its Ultreon 3.0 Software, an AI-powered imaging platform for coronary procedures. This development highlights Abbott’s ongoing innovation in medical technology. Meanwhile, the company reported mixed first-quarter results, with worldwide sales increasing by 1% and adjusted earnings per share meeting expectations. However, revenue missed expectations on an organic growth basis, with particular weaknesses noted in the diabetes and respiratory segments.
Several analyst firms have adjusted their price targets for Abbott Laboratories following these results. Leerink Partners lowered its target to $106, citing mixed performance, while Bernstein SocGen reduced its target to $110, noting flat growth compared to the previous quarter. Piper Sandler decreased its price target to $115, pointing out underperformance in the medical device segment, especially in diabetes sales. TD Cowen also cut its target to $115 due to lowered organic guidance and product weaknesses. Despite these adjustments, some firms, like Bernstein SocGen and Piper Sandler, maintained positive ratings, indicating varied analyst perspectives on Abbott’s future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.